KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) EBT: 2009-2024

Historic EBT for Acadia Pharmaceuticals (ACAD) over the last 16 years, with Dec 2024 value amounting to $258.1 million.

  • Acadia Pharmaceuticals' EBT rose 14.93% to $44.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $273.7 million, marking a year-over-year increase of 100.19%. This contributed to the annual value of $258.1 million for FY2024, which is 605.67% up from last year.
  • Per Acadia Pharmaceuticals' latest filing, its EBT stood at $258.1 million for FY2024, which was up 605.67% from -$51.0 million recorded in FY2023.
  • Acadia Pharmaceuticals' EBT's 5-year high stood at $258.1 million during FY2024, with a 5-year trough of -$281.0 million in FY2020.
  • Its 3-year average for EBT is -$2.1 million, with a median of -$51.0 million in 2023.
  • Per our database at Business Quant, Acadia Pharmaceuticals' EBT dropped by 27.41% in 2022 and then skyrocketed by 605.67% in 2024.
  • Acadia Pharmaceuticals' EBT (Yearly) stood at -$281.0 million in 2020, then skyrocketed by 40.38% to -$167.5 million in 2021, then fell by 27.41% to -$213.4 million in 2022, then surged by 76.09% to -$51.0 million in 2023, then spiked by 605.67% to $258.1 million in 2024.